Literature DB >> 17307359

Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.

Anton V Bieliauskas1, Sujith V W Weerasinghe, Mary Kay H Pflum.   

Abstract

Inhibitors of histone deacetylase (HDAC) proteins such as suberoylanilide hydroxamic acid (SAHA) have emerged as effective therapeutic anti-cancer agents. To better understand the structural requirements of HDAC inhibitors, a small molecule library with a variety of substituents attached adjacent to the metal binding hydroxamic acid of SAHA was synthesized. The presence of a substituent adjacent to the hydroxamic acid led to an 800- to 5000-fold decrease in inhibition compared to SAHA. The observed results have implications for drug design, suggesting that HDAC inhibitors with substituents near the metal binding moiety will have inhibitory activities in the micromolar rather than nanomolar range.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307359      PMCID: PMC1896371          DOI: 10.1016/j.bmcl.2007.01.117

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  Design and synthesis of a novel class of histone deacetylase inhibitors.

Authors:  R Lavoie; G Bouchain; S Frechette; S H Woo; E Abou-Khalil; S Leit; M Fournel; P T Yan; M C Trachy-Bourget; C Beaulieu; Z Li; J Besterman; D Delorme
Journal:  Bioorg Med Chem Lett       Date:  2001-11-05       Impact factor: 2.823

2.  Vorinostat.

Authors:  Steven Grant; Chris Easley; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

Review 3.  Anticancer activities of histone deacetylase inhibitors.

Authors:  Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

4.  A series of novel, potent, and selective histone deacetylase inhibitors.

Authors:  Philip Jones; Sergio Altamura; Prasun K Chakravarty; Ottavia Cecchetti; Raffaele De Francesco; Paola Gallinari; Raffaele Ingenito; Peter T Meinke; Alessia Petrocchi; Michael Rowley; Rita Scarpelli; Sergio Serafini; Christian Steinkühler
Journal:  Bioorg Med Chem Lett       Date:  2006-09-20       Impact factor: 2.823

Review 5.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

6.  Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.

Authors:  C J Phiel; F Zhang; E Y Huang; M G Guenther; M A Lazar; P S Klein
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

7.  Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.

Authors:  M Jung; G Brosch; D Kölle; H Scherf; C Gerhäuser; P Loidl
Journal:  J Med Chem       Date:  1999-11-04       Impact factor: 7.446

8.  Synthesis and biological evaluation of new citrate-based siderophores as potential probes for the mechanism of iron uptake in mycobacteria.

Authors:  Hongyan Guo; Saleh A Naser; George Ghobrial; Otto Phanstiel
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

9.  Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.

Authors:  Shinichi Uesato; Manabu Kitagawa; Yasuo Nagaoka; Taishi Maeda; Hiroshi Kuwajima; Takao Yamori
Journal:  Bioorg Med Chem Lett       Date:  2002-05-20       Impact factor: 2.823

10.  Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Authors:  Soon Hyung Woo; Sylvie Frechette; Elie Abou Khalil; Giliane Bouchain; Arkadii Vaisburg; Naomy Bernstein; Oscar Moradei; Silvana Leit; Martin Allan; Marielle Fournel; Marie-Claude Trachy-Bourget; Zuomei Li; Jeffrey M Besterman; Daniel Delorme
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

View more
  17 in total

1.  The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Authors:  Sun Ea Choi; Sujith V W Weerasinghe; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2011-08-12       Impact factor: 2.823

2.  Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

Authors:  C T Chan; J Qi; W Smith; R Paranol; R Mazitschek; N West; R Reeves; G Chiosis; S L Schreiber; J E Bradner; R Paulmurugan; S S Gambhir
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

3.  Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.

Authors:  Ahmed T Negmeldin; Geetha Padige; Anton V Bieliauskas; Mary Kay H Pflum
Journal:  ACS Med Chem Lett       Date:  2017-02-07       Impact factor: 4.345

4.  A histone deacetylase-dependent screen in yeast.

Authors:  Sujith V W Weerasinghe; Magdalene Wambua; Mary Kay H Pflum
Journal:  Bioorg Med Chem       Date:  2010-09-20       Impact factor: 3.641

5.  Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold.

Authors:  Erinprit K Singh; Suchitra Ravula; Chung-Mao Pan; Po-Shen Pan; Robert C Vasko; Stephanie A Lapera; Sujith V W Weerasinghe; Mary Kay H Pflum; Shelli R McAlpine
Journal:  Bioorg Med Chem Lett       Date:  2008-03-20       Impact factor: 2.823

6.  Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.

Authors:  Sheeba Varghese; Thulani Senanayake; Tracey Murray-Stewart; Kim Doering; Alison Fraser; Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2008-03-19       Impact factor: 7.446

7.  Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.

Authors:  Anton V Bieliauskas; Sujith V W Weerasinghe; Ahmed T Negmeldin; Mary Kay H Pflum
Journal:  Arch Pharm (Weinheim)       Date:  2016-04-09       Impact factor: 3.751

8.  The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.

Authors:  Ahmed T Negmeldin; Joseph R Knoff; Mary Kay H Pflum
Journal:  Eur J Med Chem       Date:  2017-10-31       Impact factor: 6.514

9.  Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors.

Authors:  Sujith V W Weerasinghe; Guillermina Estiu; Olaf Wiest; Mary Kay H Pflum
Journal:  J Med Chem       Date:  2008-08-27       Impact factor: 7.446

10.  The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.

Authors:  Sun Ea Choi; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2012-10-02       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.